TCT Meeting 2022 GVHD News
Advertisement
Researchers examined outcomes in peripheral blood haplo-HCT and their relation to pre-operation measurable residual disease.
The phase II study had enrolled 63 patients at the time of the interim analysis.
Venkata S. Thammineni, MD, and colleagues conducted a meta-analysis to assess the effect of graft CD on allo-PBSCT outcomes.
Researchers examined the relationship between extracellular vesicle antigen expression and their microRNA cargo.
The poster advanced a total of 27 "candidate protein biomarkers which may predict occurrence of aGVHD."
A studyobserved “encouragingly” positive results in reducing severe acute graft-versus-host disease (aGVHD).
The data were presented by the study’s lead author, Meredith Jo McAdams, MD, at the TCT 2022 Tandem Meetings.
Researchers presented updated data from the phase Ib/II EQUATE trial.
Researchers sought to characterize outcomes of pediatric patients who developed SR-aGVHD after allogeneic HSCT.
A poster investigated the clinical outcomes in German patients who developed acute graft-versus-host disease.
The study sought to improve graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplant.
Researchers theorized that inhibiting JAK1 with itacitinib could prevent aGVHD and CRS in certain patients.
Orca-T appeared to yield a reduction in chronic graft-versus-host disease.
Researchers evaluated the presence of innate lymphoid cells in unmanipulated, lymphocyte-replete HCT grafts.
Researchers evaluated the rate of failure-free survival after belumosudil treatment for chronic graft-versus-host disease.
The investigators measured plasma vitamin E levels with high-performance liquid chromatography.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.